Document Detail

Comparative safety and efficacy of urokinase and recombinant tissue plasminogen activator for peripheral arterial occlusion: a meta-analysis.
MedLine Citation:
PMID:  16506349     Owner:  NLM     Status:  MEDLINE    
STUDY OBJECTIVE: To evaluate differences in the efficacy and safety of recombinant tissue plasminogen activator (rt-PA) and urokinase in the treatment of peripheral arterial occlusion. DESIGN: Systematic review and meta-analysis of prospective comparative trials. DATA SOURCE: PubMed/MEDLINE database from 1966-October 2004. MEASUREMENTS AND MAIN RESULTS: The literature was systematically searched to identify prospective comparative trials of urokinase and rt-PA for the treatment of peripheral arterial occlusion. The primary outcome measure was successful complete lysis of the occlusion. Other outcome measures were hemorrhage (major, minor, or combined), intracranial hemorrhage, limb loss, and mortality. Six trials were identified, five of which were randomized. On meta-analysis, the rate of clot lysis was higher with rt-PA than with urokinase (odds ratio [OR] 1.54, 95% confidence interval [CI] 1.12-2.10, p=0.007). However, urokinase was associated with lower rates of minor (OR 0.52, 95% CI 0.28-0.97, p=0.04) and total (OR 0.51, 95% CI 0.29-0.91, p=0.02) bleeding. Rates of major hemorrhage, intracranial hemorrhage, limb loss, and mortality were similar between agents. CONCLUSION: Urokinase was less effective than rt-PA in successfully lysing acute peripheral arterial occlusion, but it was associated with lower rates of total and minor bleeding. Overall, rt-PA was a reasonable substitute for urokinase, now that urokinase has been removed from the market in the United States. However, judicious monitoring for minor bleeding is necessary.
Stephen Sander; C Michael White; Craig I Coleman
Related Documents :
12799729 - Relationship of peripheral arterial compliance and standard cardiovascular risk factors.
11394719 - The influence of misnaming on object recognition: a case of multimodal agnosia.
17931689 - The upper paleolithic burial area at predmostí: ritual and taphonomy.
9413649 - Video fluorescein imaging of the skin: description of an overviewing technique for func...
8796679 - Pulmonary parenchymal manifestations surrounding small peripheral masses: pathologic co...
1942159 - Peripheral arterial shotgun missile emboli: diagnostic and therapeutic management--case...
1000619 - Coronary artery spasm: the effect of cardiovascular laboratory premedication practice.
7661799 - Venous allografts: a useful alternative to venous autografts in digestive surgery.
9551589 - Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodeling.
Publication Detail:
Type:  Comparative Study; Journal Article; Meta-Analysis    
Journal Detail:
Title:  Pharmacotherapy     Volume:  26     ISSN:  0277-0008     ISO Abbreviation:  Pharmacotherapy     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2006-02-28     Completed Date:  2006-06-14     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  United States    
Other Details:
Languages:  eng     Pagination:  51-60     Citation Subset:  IM    
Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arterial Occlusive Diseases / complications,  drug therapy*,  mortality
Hemorrhage / epidemiology,  etiology,  mortality
Odds Ratio
Plasminogen Activators / adverse effects,  therapeutic use*
Randomized Controlled Trials as Topic
Recombinant Proteins / adverse effects,  therapeutic use
Urokinase-Type Plasminogen Activator / adverse effects*,  therapeutic use*
Reg. No./Substance:
0/Recombinant Proteins; EC 3.4.21.-/Plasminogen Activators; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antibiotic selection and resistance issues with fluoroquinolones and doxycycline against bioterroris...
Next Document:  Pharmacotherapy for idiopathic pulmonary arterial hypertension during the past 25 years.